Tenofovir©\Based Rescue Therapy for Advanced Liver Disease in 6 Patients Coinfected with HIV and Hepa

[Guest guest]

Clinical Infectious Diseases 2008;46:e28¨Ce30

1058-4838/2008/4603-00E2$15.00

DOI: 10.1086/525857

BRIEF REPORT

Tenofovir©\Based Rescue Therapy for Advanced Liver Disease in 6 Patients

Coinfected with HIV and Hepatitis B Virus and Receiving Lamivudine

Guti¨¦rrez,1

Silvia Guillemi,1

Jahnke,1

Valentina Montessori,1,2

P. Harrigan,1,2 and

Julio S. G. Montaner1,2

1BC Centre for Excellence in HIV/AIDS, St. ¡¯s Hospital, and 2Faculty of

Medicine, University of British Columbia, Vancouver, Canada

Received 9 July 2007; accepted 11 October 2007; electronically published 20

December 2007.

Reprints or correspondence: Dr. Julio S. G. Montaner, Division of AIDS, Dept. of

Medicine, St. ¡¯s Hospital/University of British Columbia, 667¨C1081 Burrard

St., Vancouver, BC V6Z 1Y6, Canada (jmontaner@...).

We summarize the clinical history and laboratory results following the

introduction of tenofovir among 6 patients coinfected with human

immunodeficiency virus (HIV) and hepatitis B virus (HBV) who presented with

severe liver disease while receiving lamivudine©\based highly active

antiretroviral therapy. In all cases, the introduction of tenofovir led to a

sustained undetectable HBV and HIV loads, with marked clinical and laboratory

improvement in liver function. We provide supporting evidence for the role of

tenofovir in the management of advanced HBV infection in HIV¨Cpositive patients

after the development of lamivudine resistance.

http://www.journals.uchicago.edu/doi/abs/10.1086/525857

_________________________________________________________________

Get the power of Windows + Web with the new Windows Live.

http://www.windowslive.com?ocid=TXT_TAGHM_Wave2_powerofwindows_012008

[Guest guest]

Clinical Infectious Diseases 2008;46:e28¨Ce30

1058-4838/2008/4603-00E2$15.00

DOI: 10.1086/525857

BRIEF REPORT

Tenofovir©\Based Rescue Therapy for Advanced Liver Disease in 6 Patients

Coinfected with HIV and Hepatitis B Virus and Receiving Lamivudine

Guti¨¦rrez,1

Silvia Guillemi,1

Jahnke,1

Valentina Montessori,1,2

P. Harrigan,1,2 and

Julio S. G. Montaner1,2

1BC Centre for Excellence in HIV/AIDS, St. ¡¯s Hospital, and 2Faculty of

Medicine, University of British Columbia, Vancouver, Canada

Received 9 July 2007; accepted 11 October 2007; electronically published 20

December 2007.

Reprints or correspondence: Dr. Julio S. G. Montaner, Division of AIDS, Dept. of

Medicine, St. ¡¯s Hospital/University of British Columbia, 667¨C1081 Burrard

St., Vancouver, BC V6Z 1Y6, Canada (jmontaner@...).

We summarize the clinical history and laboratory results following the

introduction of tenofovir among 6 patients coinfected with human

immunodeficiency virus (HIV) and hepatitis B virus (HBV) who presented with

severe liver disease while receiving lamivudine©\based highly active

antiretroviral therapy. In all cases, the introduction of tenofovir led to a

sustained undetectable HBV and HIV loads, with marked clinical and laboratory

improvement in liver function. We provide supporting evidence for the role of

tenofovir in the management of advanced HBV infection in HIV¨Cpositive patients

after the development of lamivudine resistance.

http://www.journals.uchicago.edu/doi/abs/10.1086/525857

_________________________________________________________________

Get the power of Windows + Web with the new Windows Live.

http://www.windowslive.com?ocid=TXT_TAGHM_Wave2_powerofwindows_012008

[Guest guest]

Clinical Infectious Diseases 2008;46:e28¨Ce30

1058-4838/2008/4603-00E2$15.00

DOI: 10.1086/525857

BRIEF REPORT

Tenofovir©\Based Rescue Therapy for Advanced Liver Disease in 6 Patients

Coinfected with HIV and Hepatitis B Virus and Receiving Lamivudine

Guti¨¦rrez,1

Silvia Guillemi,1

Jahnke,1

Valentina Montessori,1,2

P. Harrigan,1,2 and

Julio S. G. Montaner1,2

1BC Centre for Excellence in HIV/AIDS, St. ¡¯s Hospital, and 2Faculty of

Medicine, University of British Columbia, Vancouver, Canada

Received 9 July 2007; accepted 11 October 2007; electronically published 20

December 2007.

Reprints or correspondence: Dr. Julio S. G. Montaner, Division of AIDS, Dept. of

Medicine, St. ¡¯s Hospital/University of British Columbia, 667¨C1081 Burrard

St., Vancouver, BC V6Z 1Y6, Canada (jmontaner@...).

We summarize the clinical history and laboratory results following the

introduction of tenofovir among 6 patients coinfected with human

immunodeficiency virus (HIV) and hepatitis B virus (HBV) who presented with

severe liver disease while receiving lamivudine©\based highly active

antiretroviral therapy. In all cases, the introduction of tenofovir led to a

sustained undetectable HBV and HIV loads, with marked clinical and laboratory

improvement in liver function. We provide supporting evidence for the role of

tenofovir in the management of advanced HBV infection in HIV¨Cpositive patients

after the development of lamivudine resistance.

http://www.journals.uchicago.edu/doi/abs/10.1086/525857

_________________________________________________________________

Get the power of Windows + Web with the new Windows Live.

http://www.windowslive.com?ocid=TXT_TAGHM_Wave2_powerofwindows_012008

[Guest guest]

Clinical Infectious Diseases 2008;46:e28¨Ce30

1058-4838/2008/4603-00E2$15.00

DOI: 10.1086/525857

BRIEF REPORT

Tenofovir©\Based Rescue Therapy for Advanced Liver Disease in 6 Patients

Coinfected with HIV and Hepatitis B Virus and Receiving Lamivudine

Guti¨¦rrez,1

Silvia Guillemi,1

Jahnke,1

Valentina Montessori,1,2

P. Harrigan,1,2 and

Julio S. G. Montaner1,2

1BC Centre for Excellence in HIV/AIDS, St. ¡¯s Hospital, and 2Faculty of

Medicine, University of British Columbia, Vancouver, Canada

Received 9 July 2007; accepted 11 October 2007; electronically published 20

December 2007.

Reprints or correspondence: Dr. Julio S. G. Montaner, Division of AIDS, Dept. of

Medicine, St. ¡¯s Hospital/University of British Columbia, 667¨C1081 Burrard

St., Vancouver, BC V6Z 1Y6, Canada (jmontaner@...).

We summarize the clinical history and laboratory results following the

introduction of tenofovir among 6 patients coinfected with human

immunodeficiency virus (HIV) and hepatitis B virus (HBV) who presented with

severe liver disease while receiving lamivudine©\based highly active

antiretroviral therapy. In all cases, the introduction of tenofovir led to a

sustained undetectable HBV and HIV loads, with marked clinical and laboratory

improvement in liver function. We provide supporting evidence for the role of

tenofovir in the management of advanced HBV infection in HIV¨Cpositive patients

after the development of lamivudine resistance.

http://www.journals.uchicago.edu/doi/abs/10.1086/525857

_________________________________________________________________

Get the power of Windows + Web with the new Windows Live.

http://www.windowslive.com?ocid=TXT_TAGHM_Wave2_powerofwindows_012008